CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
13 juin 2022 06h30 HE
|
Centogene NV
Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE’s genetic testing and Biodatabank identify causative mutations, including the UGT1A1 and PKLR genes, and...
CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally
28 avr. 2022 06h30 HE
|
Centogene NV
Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases CENTOGENE and Takeda extend contract to continue providing access to genetic...
CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development
20 janv. 2022 06h30 HE
|
Centogene NV
CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC using AINPC is a rare genetic disease occurring in...
CENTOGENE Extends Partnership With Takeda
14 avr. 2021 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENE to Report First Half 2020 Financial Results on September 23, 2020
16 sept. 2020 08h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass., and ROSTOCK, Germany & BERLIN, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENE and Evotec Expand Collaboration Into Gaucher Disease
20 août 2020 01h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and HAMBURG, Germany and BERLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that...
CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs
27 juil. 2020 08h00 HE
|
CENTOGENE GmbH
The combination of real-life data sets in rare diseases with innovative big data/artificial intelligence/novel scientific computational knowledge will transform biomedical research, product...
CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares
09 juil. 2020 19h19 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene” or the “Company”), a commercial-stage company focused on rare diseases...
CENTOGENE Announces the Scientific Publication of a holistic solution in the preventive testing of COVID-19
09 juil. 2020 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, today announced that...
CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares
07 juil. 2020 18h16 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...